Before you sell to, join or invest in Retension Pharmaceuticals, Inc.
MentionFox check on Retension Pharmaceuticals, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/retension-pharmaceuticals-inc-form-d-25000001
Check Retension Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Retension Pharmaceuticals, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Retension Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-06.
Retension Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 6, 2025. The filing reports $12.29M sold. Its industry group is Pharmaceuticals. It names Eric Keller (Executive Officer, Director), Michael Berendt (Director), Donald Olds (Director) (SEC Form D, May 6, 2025).
Is this your company?
Sell to companies like Retension Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Retension Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Retension Pharmaceuticals, Inc., from the filings we hold.
Stonehaven, LLC received sales compensation on this raise and on 9 other raises we hold, nearest in date first:
Collage Venture Partners, LLC received sales compensation on this raise and on 8 other raises we hold, nearest in date first:
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Retension Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Retension Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Retension Pharmaceuticals, Inc. →Get the full cited report on Retension Pharmaceuticals, Inc.
What the filing shows about Retension Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Retension Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Retension Pharmaceuticals, Inc.'s address as C/O Redux Therapeutics, LLC, 902 Turkey Run Road, Mclean, VA 22101.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Retension Pharmaceuticals, Inc. See pricing
Retension Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 2002988) and has filed since 2023-12-05. 3 filings are on record, the latest on 2025-05-06.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Retension Pharmaceuticals, Inc.'s Form D of 2025-05-06 names Eric Keller, Michael Berendt and Donald Olds as its officers, directors or promoters.
Its new offerings report $18.11M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing RTN-001 and next-generation therapies for uncontrolled hypertension.
The title and description the site itself served, answering 200, after redirecting from https://retensionpharmaceuticals.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Eric Keller is named as Executive Officer and Director on the Form D that Retension Pharmaceuticals, Inc. filed with the SEC on 6 May 2025, one of 3 people that filing names.
Michael Berendt is named as Director on the Form D that Retension Pharmaceuticals, Inc. filed with the SEC on 6 May 2025, one of 3 people that filing names.
Donald Olds is named as Director on the Form D that Retension Pharmaceuticals, Inc. filed with the SEC on 6 May 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-05-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Retension Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Retension Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Retension Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Retension Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Retension Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-04 (retensionpharmaceuticals.com).
Each opens in a new tab, filled in for Retension Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Washington, DC
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/retension-pharmaceuticals-inc-form-d-25000001